223 related articles for article (PubMed ID: 32920739)
21. Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer.
Gong TQ; Jiang YZ; Shao C; Peng WT; Liu MW; Li DQ; Zhang BY; Du P; Huang Y; Li FF; Li MY; Han ZL; Jin X; Ma D; Xiao Y; Yang PY; Qin J; Shao ZM; Zhu W
Cell Rep; 2022 Mar; 38(9):110460. PubMed ID: 35235781
[TBL] [Abstract][Full Text] [Related]
22. Integrated Multi-Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal-Like Triple-Negative Breast Cancer.
Jin MS; Lee H; Woo J; Choi S; Do MS; Kim K; Song MJ; Kim Y; Park IA; Han D; Ryu HS
Proteomics Clin Appl; 2018 Sep; 12(5):e1700125. PubMed ID: 29476606
[TBL] [Abstract][Full Text] [Related]
23. Mascot file parsing and quantification (MFPaQ), a new software to parse, validate, and quantify proteomics data generated by ICAT and SILAC mass spectrometric analyses: application to the proteomics study of membrane proteins from primary human endothelial cells.
Bouyssié D; Gonzalez de Peredo A; Mouton E; Albigot R; Roussel L; Ortega N; Cayrol C; Burlet-Schiltz O; Girard JP; Monsarrat B
Mol Cell Proteomics; 2007 Sep; 6(9):1621-37. PubMed ID: 17533220
[TBL] [Abstract][Full Text] [Related]
24. Shotgun proteomics of archival triple-negative breast cancer samples.
Gámez-Pozo A; Ferrer NI; Ciruelos E; López-Vacas R; Martínez FG; Espinosa E; Vara JÁ
Proteomics Clin Appl; 2013 Apr; 7(3-4):283-91. PubMed ID: 23436753
[TBL] [Abstract][Full Text] [Related]
25. Quantitative proteomics reveals middle infrared radiation-interfered networks in breast cancer cells.
Chang HY; Li MH; Huang TC; Hsu CL; Tsai SR; Lee SC; Huang HC; Juan HF
J Proteome Res; 2015 Feb; 14(2):1250-62. PubMed ID: 25556991
[TBL] [Abstract][Full Text] [Related]
26. Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
Lanceta L; Lypova N; O'Neill C; Li X; Rouchka E; Chesney J; Imbert-Fernandez Y
Breast Cancer Res Treat; 2021 Apr; 186(3):677-686. PubMed ID: 33599863
[TBL] [Abstract][Full Text] [Related]
27. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
28. Proteomic analysis of talazoparib resistance in triple-negative breast cancer cells.
Guney Eskiler G; Yanar S; Akpinar G; Kasap M
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22678. PubMed ID: 33325624
[TBL] [Abstract][Full Text] [Related]
29. SWATH Based Quantitative Proteomics Reveals Significant Lipid Metabolism in Early Myopic Guinea Pig Retina.
Bian J; Sze YH; Tse DY; To CH; McFadden SA; Lam CS; Li KK; Lam TC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946922
[TBL] [Abstract][Full Text] [Related]
30. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
31. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
[TBL] [Abstract][Full Text] [Related]
33. Targeted proteomics using parallel reaction monitoring confirms salivary proteins indicative of metastatic triple-negative breast cancer.
Giri K; Maity S; Ambatipudi K
J Proteomics; 2022 Sep; 267():104701. PubMed ID: 35995384
[TBL] [Abstract][Full Text] [Related]
34. Quantitative label-free mass spectrometry using contralateral and adjacent breast tissues reveal differentially expressed proteins and their predicted impacts on pathways and cellular functions in breast cancer.
Gomig THB; Cavalli IJ; Souza RLR; Vieira E; Lucena ACR; Batista M; Machado KC; Marchini FK; Marchi FA; Lima RS; de Andrade Urban C; Cavalli LR; Ribeiro EMSF
J Proteomics; 2019 May; 199():1-14. PubMed ID: 30772490
[TBL] [Abstract][Full Text] [Related]
35. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
[TBL] [Abstract][Full Text] [Related]
36. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
37. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
38. Triple-negative Breast Carcinoma With Apocrine and Histiocytoid Features: A Clinicopathologic and Molecular Study of 18 Cases.
Wang Y; Hacking SM; Li Z; Graff SL; Yang D; Tan L; Liu F; Zhang T; Zhao Z; Luo S; Du P; Jia S; Cheng L
Am J Surg Pathol; 2023 Sep; 47(9):1011-1018. PubMed ID: 37310016
[TBL] [Abstract][Full Text] [Related]
39. Systems pharmacology in combination with proteomics reveals underlying mechanisms of Xihuang pill against triple-negative breast cancer.
Xu X; Zhang J; Zhang Z; Wang M; Liu Y; Li X
Bioengineered; 2020 Dec; 11(1):1170-1188. PubMed ID: 33092442
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
